Clinical and economic assessment of different general population strategies of pertussis vaccine booster regarding number of doses and age of application for reducing whooping cough disease burden: A systematic review

Vaccine

Volumn 26, Issue 52, 2008, Pages 6768-6776

  Rodríguez Cobo, Iria ^a,b   Chen, Yen Fu ^c   Olowokure, Babatunde ^c,d   Litchfield, Ian ^c  

^a HOSPITAL JUAN CANALEJO   (Spain)

^b IASIST   (Spain)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Booster strategy; Economic evaluation; Pertussis vaccination; Systematic review

Indexed keywords

PERTUSSIS VACCINE;

AGE; BORDETELLA PERTUSSIS; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDICATION; HERD IMMUNITY; HUMAN; INFECTION PREVENTION; MATHEMATICAL MODEL; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PERTUSSIS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; VACCINATION;

ADOLESCENT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; COST OF ILLNESS; DATA INTERPRETATION, STATISTICAL; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INFANT; PERTUSSIS VACCINE; POPULATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; WHOOPING COUGH;

EID: 56949090798     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.09.042     Document Type: Review

References (36)

1. Pertussis vaccines. WHO Position Paper. Wkly Epidemiol Rec 2005;(4):31-39.
2. American Academy of Pediatrics Commitee on Infectious Diseases. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. Pediatrics 117 3 (2006) 965-978
3. Baron S., Begue P., and Grimprel E. Epidemiology of pertussis in industrialised countries. Cahiers Santé 4 3 (1994) 195-200
4. Cherry J.D. The role of Bordetella pertussis infections in adults in the epidemiology of pertussis. Dev Biol Stand 89 (1997) 181-186
5. Therre E., and Baron S. Pertussis immunization in Europe. The situation in late 1999. Eurosurveillance 5 1 (2000) 6-10
6. Forsyth K., Tan T., von Konig C.H., Caro J.J., and Plotkin S. Potential strategies to reduce the burden of pertussis. Pediatr Infect Dis J 24 5 Suppl (2005) S69-S74
7. Campins-Marti M., Cheng H.K., Forsyth K., Guiso N., Halperin S., and Huang L.M. Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration. Vaccine 20 5-6 (2001) 641-646
8. Purdy K.W., Hay J.W., Botteman M.F., and Ward J.I. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis 39 1 (2004) 20-28
9. Mitka M. Age range widens for pertussis vaccine: boosters advised for adolescents and adults. JAMA 295 8 (2006) 871-872
10. Jacquet J.M., Begue P., Grimprel E., Reinert P., Sandbu S., Silfverdal S.A., et al. Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: a review. Vaccine 24 13 (2006) 20
11. Glode M., Joffe L., Reisinger K., Blatter M., Plotkin S., Watson B., et al. Safety and immunogenicity of acellular pertussis vaccine combined with diphtheria and tetanus toxoids in 17- to 24-month-old children. Pediatr Infect Dis J 11 (1992) 530-535
12. Just M., Bogaerts H., Boscia J., Moonsammy G., and Andre F. Safety and immunogenicity of a booster dose of a candidate acellular pertussis vaccine in healthy children. Pediatr Res 29 Suppl (1991) 158A
13. NHS Centre for Reviews and Dissemination. Undertaking Systematic Reviews of Research on Effectiveness. CRD's Guidance for those Carrying Out or Commissioning Reviews. Report No.4. York Publishing Services; 2001.
14. Learning & Development Public Health Resource Unit-Oxford. URL: http://www.phru.nhs.uk/casp/casp.htm.
15. Philips Z., Ginnelly L., Sculpher M., Claxton K., Golder S., Riemsma R., et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 8 36 (2004) 1-179
16. Hamed A., Borderon J.C., Baron S., and Ramponi N. Pertussis in Indre-et-Loire during 1993 Results of a questionnaire sent to family practitioners and pediatricians about suspected cases and attitude toward pertussis immunization. Med Mal Infect 25 3 BIS (1995) 522-524
17. Andrews R., Herceg A., and Roberts C. Pertussis notifications in Australia 1991 to 1997. Commun Dis Intell 21 11 (1997) 145-148
18. Torvaldsen S., and McIntyre P.B. Effect of the preschool pertussis booster on national notifications of disease in Australia. Pediatr Infect Dis J 22 11 (2003) 956-959
19. De Greeff S.C., Schellekens J.F., Mooi F.R., and de Melker H.E. Effect of vaccination against pertussis on the incidence of pertussis in The Netherlands, 1996-2003. Ned Tijdschr Geneeskd 149 17 (2005) 937-943
20. De Serres G., Shadmani R., Boulianne N., Duval B., Rochette L., Douville F.M., et al. Effectiveness of a single dose of acellular pertussis vaccine to prevent pertussis in children primed with pertussis whole cell vaccine. Vaccine 19 20-22 (2001) 3004-3008
21. González M.F., Moreno C.A., Amela H.C., Pachón D.A., García del B.A., Herrero C.C., et al. A study of whooping cough epidemic outbreak in Castellón, Spain. Rev Esp Salud Publica 76 4 (2002) 311-319
22. Blennow M., and Granstrom M. Long term serologic follow-up after pertussis immunization. Pediatr Infect Dis J 9 (1990) 21-26
23. Tindberg Y., Blennow M., and Granstrom M. A ten year follow-up after immunization with a two component acellular pertussis vaccine. Pediatr Infect Dis J 18 4 (1999) 361-365
24. Hviid A., Stellfeld M., Wohlfahrt J., Andersen P.H., and Melbye M. The impact of pre-school booster vaccination of 4-6-year-old children on pertussis in 0-1-year-old children. Vaccine 24 9 (2006) 1401-1407
25. Aguas R., Gonçalves G., and Gomes M.G. Pertussis: increasing disease as a consequence of reducing transmission. Lancet Infect Dis 6 2 (2006) 112-117
26. Van Rie A., and Hethcote H.W. Adolescent and adult pertussis vaccination: computer simulations of five new strategies. Vaccine 22 (2004) 3154-3165
27. Hethcote H.W. Simulations of pertussis epidemiology in the United States: effects of adult booster vaccinations. Math Biosci 158 1 (1999) 47-73
28. Hethcote H.W., Horby P., and McIntyre P. Using computer simulations to compare pertussis vaccination strategies in Australia. Vaccine 22 17-18 (2004) 2181-2191
29. Iskedjian M., Walker J.H., De S.G., and Einarson T.R. Economic evaluation of an extended acellular pertussis vaccine program for adolescents in Quebec, Canada. Paediatr Drugs 7 2 (2005) 123-136
30. Iskedjian M., Walker J.H., and Hemels M.E. Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada. Vaccine 22 31-32 (2004) 4215-4227
31. Stevenson M., Beard S., Finn A., and Brennan A. Estimating the potential health gain and cost consequences of introducing a pre-school DTPa pertussis booster into the UK child vaccination schedule. Vaccine 20 13-14 (2002) 1778-1786
32. Edmunds W.J., Brisson M., Melegaro A., and Gay N.J. The potential costeffectiveness of acellular pertussis booster vaccination in England and Wales. Vaccine 20 9-10 (2002) 1316-1330
33. Caro J.J., Getsios D., El-Hadi W., Payne K., and O'Brien J.A. Pertussis immunization of adolescents in the United States: an economic evaluation. Pediatr Infect Dis J 24 5 Suppl (2005) S75-S82
34. Lee G.M., Lebaron C., Murphy T.V., Lett S., Schauer S., Lieu T.A., et al. Pertussis in adolescents and adults: should we vaccinate?. Pediatrics 115 6 (2005) 1675-1684
35. Lee L.H., and Pichichero M.E. Costs of illness due to Bordetella pertussis in families. Arch Fam Med 9 10 (2000) 989-996
36. Shekelle P.G., Woolf S.H., Eccles M., and Grimshaw J. Clinical guidelines: developing clinical guidelines. BMJ 318 7183 (1999) 593-596